Tyrian purple indirubins: A source of GSK-3 inhibitors;La pourpre de Méditerranée, une source inattendue d'inhibiteurs de GSK-3

Medecine/Sciences

Volumn 20, Issue 5, 2004, Pages 516-518

  Meijer, Laurent ^a  

^a STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYCLIN A; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; TYRIAN PURPLE INDIRUBIN; UNCLASSIFIED DRUG;

CELL DIVISION; CRYSTALLIZATION; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; MOLLUSC; NOTE; PLASMODIUM FALCIPARUM;

MOLLUSCA; PLASMODIUM FALCIPARUM; TYRIA;

EID: 2442438812     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004205516     Document Type: Note

References (14)

1. Cooksey CJ. Tyrian purple: 6,6′-dibromoindigo and related compounds. Molecules 2001; 6: 736-69.
2. Friedlander P. Uber den Farstoff des antikeen Purpurs aus Murex brandaris. 1909; 765-70.
3. Balfour-Paul J. Indigo. British Museum Press. 1998: 264 p.
4. Hoessel R, Leclerc S, Endicott J, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1: 60-7.
5. Damiens E, Baratte B, Marie D, et al. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001; 20: 3786-97.
6. Davies TG, Tunnah P, Meijer L, et al. Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001; 9: 389-97.
7. Holton S, Merckx A, Burgess D, et al. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure 2003; 11: 1329-37.
8. Leclerc S, Garnier M, Hoessel R, et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease - a property common to most CDK inhibitors? J Biol Chem 2001; 276: 251-60.
9. Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255-66.
10. Polychronopoulos P, Magiatis P, Skaltsounis L, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004; 47: 935-46.
11. Fischer PM. CDK versus GSK-3 inhibition: a purple haze no longer? Chem Biol 2003; 10: 1144-6.
12. Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3 specific inhibitor. Nat Med 2004; 10: 55-63.
13. Dolique R. Balard, so vie, son œuvre à Montpellier de 1802 à 1840. Rev Hist Pharm 1977; 232: 13-27.
14. Lacaze-Duthiers H. Mémoire sur la Pourpre. An Sci Nat Zool 1859; 12: 5-84.